Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling

2 Nov 2022

Abstract excerpt

The limited efficacy of immune checkpoint inhibitor treatment in triple-negative breast cancer (TNBC) patients is attributed to sparse or unresponsive tumor-infiltrating lymphocytes, but the mechanisms that lead to a therapy resistant tumor immune microenvironment are incompletely known. Here we show a strong correlation between MYC expression and loss of immune signatures in human TNBC. In mouse models of TNBC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune cells in cancer
Share to interferon and immune responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36323660
DOI: 10.1038/s41467-022-34000-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signalingPMID 36323660Read ↗

MYC promotes immune-suppression in TNBC via inhibition of IFN signalingSemantic proximity Read ↗

MYC controls STING levels to downregulate inflammatory signaling in breast cancer cells upon DNA damageSemantic proximity Read ↗

Combinatorial Immunotherapies Overcome MYC-Driven Immune EvasionSemantic proximity Read ↗

MYC Overexpression Drives Immune Evasion in Human Cancer that is Reversible Through Restoration of Pro-Inflammatory MacrophagesSemantic proximity Read ↗

A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapiesSemantic proximity Read ↗

Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine triple-negative breast cancerSemantic proximity Read ↗

MYC Induces Immunotherapy and IFNγ Resistance Through Downregulation of JAK2Semantic proximity Read ↗

Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast CancersSemantic proximity Read ↗

MERTK inhibition cooperates with immunomodulatory cyclophosphamide to induce CXCL9⁺ monocyte-macrophage programming and durable anti-tumor immunity in triple negative breast cancerSemantic proximity Read ↗

Macrophages expressing chimeric cytokine receptors have an inflammatory phenotype and anti-tumoral activity upon IL-10 or TGFβ stimulationSemantic proximity Read ↗

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancersSemantic proximity Read ↗

Clinical relevance of the immune contexture and AXL kinase in triple-negative breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.